MP07-09 ALDO-KETO-REDUCTASE 1C3 EXPRESSION IS AN INDEPENDENT RISK FACTOR FOR OCCURRENCE OF CASTRATION RESISTANT PROSTATE CANCER IN HIGH RISK PROSTATE CANCER TREATED WITH NEOADJUVANT THERAPY AND PROSTATECTOMY

Abstract

You have accessJournal of UrologyProstate Cancer: Markers II1 Apr 2016MP07-09 ALDO-KETO-REDUCTASE 1C3 EXPRESSION IS AN INDEPENDENT RISK FACTOR FOR OCCURRENCE OF CASTRATION RESISTANT PROSTATE CANCER IN HIGH RISK PROSTATE CANCER TREATED WITH NEOADJUVANT THERAPY AND PROSTATECTOMY Yasuhiro Hashimoto, Hiromichi Iwamura, Atsushi Imai, Shingo Hatakeyama, Takahiro Yoneyama, Takuya Koie, and Chikara Ohyama Yasuhiro HashimotoYasuhiro Hashimoto More articles by this author , Hiromichi IwamuraHiromichi Iwamura More articles by this author , Atsushi ImaiAtsushi Imai More articles by this author , Shingo HatakeyamaShingo Hatakeyama More articles by this author , Takahiro YoneyamaTakahiro Yoneyama More articles by this author , Takuya KoieTakuya Koie More articles by this author , and Chikara OhyamaChikara Ohyama More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.2212AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Aldo-keto reductase family 1 member C3 (AKR1C3) is a key steroidogenic enzyme that is implicated in the development of castration-resistant prostate cancer (CRPC). In this study, we examined AKR1C3 expression in surgical specimens of high risk prostate cancer treated with neoadjuvant LHRH + EMP, and we investigate the correlation between the expression level of AKR1C3 and the occurrence of CRPC. METHODS High-risk Pca was defined by the D'Amico stratification system. A total of 103 patients with high-risk Pca were enrolled in this study from July 2005 to August 2010. The LHRH + EMP therapy included the administration of the LHRH agonist and 280 mg/day of EMP for six months before the radical prostatectomy. BCR was defined as the prostate-specific antigen (PSA) levels greater than 0.2 ng/mL after the prostatectomy. Castration-resistant prostate cancer (CRPC) is defined by PSA or radiographic progression in the castrate levels of testosterone (< 50 ng/dL). Along with the routine pathological assessment, AKR1C3 expression was evaluated in tissue microarray analysis (TMA) in all patients. A multivariable Cox proportional hazards model was used to evaluate the association between CRPC and clinical data. RESULTS The average patient age was 67.2 (49 to 78), and the median initial PSA level was 18.8 ng/mL (4.2-95.6). At a median follow-up period of 79.5 months, BCR occurred in 41 patients (39.8%) and CRPC occurred in nine patients (8.7%). In TMA, overexpression of AKR1C3 was seemed in 14 patients (13.6%). 5-year CRPC free survival rate of AKR1C3(+) patients (64.2%) was significantly lower than that of AKR1C3(-) patients (97.6%). (Log-rank test: p < 0.001) On multivariable analysis, AKR1C3 expression is an independent risk factor for occurrence of CRPC in this study. (p=0.044) CONCLUSIONS Although the present study was small and preliminary, overexpression of AKR1C3 is an independent risk factor for occurrence of CRPC in the high risk prostate cancer treated with neoadjuvant LHRH + EMP and prostatectomy. Further study is warranted to elucidate its clinical significance. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e79-e80 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Yasuhiro Hashimoto More articles by this author Hiromichi Iwamura More articles by this author Atsushi Imai More articles by this author Shingo Hatakeyama More articles by this author Takahiro Yoneyama More articles by this author Takuya Koie More articles by this author Chikara Ohyama More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...